

Amendments to the Claims

The following listing of claims will replace all prior versions and listings of claims in the application.

1. (Currently amended) A method for the treatment of gastrointestinal disorders comprising the oral administration of an aqueous suspension via a gastric tube of a or syringe to a patient in need of such treatment, wherein the aqueous suspension comprises (a) an aqueous carrier and (b) a solid composition comprising a therapeutically effective amount of an acid labile proton pump inhibitor compound in the form of a multiple of enteric coating layered pellets in a medium in the treatment of gastrointestinal disorders, wherein the pellets are in admixture with at least one or more pharmaceutically acceptable thickener which forms a viscous medium when dispersed in the aqueous carrier ~~thickeners and an aqueous carrier and the thickener is capable of forming a viscous medium when dispersed in the aqueous carrier and the formed aqueous suspension is administered through a gastric tube or syringe to a patient in need of such a treatment.~~
2. (Currently amended) The method according to claim 1, wherein the thickener is selected from the group consisting of starch, xanthan gum, carrageenan, guar gum, locust bean gum, tragacanth, gelatin, pectin, ~~and~~ modified cellulose derivatives and combinations thereof alone or in any combination.
3. (Original) The method according to claim 1, wherein the thickener is selected from starch and xanthan gum.
4. (Currently amended) The method according to claim 1, wherein the solid composition ~~further in addition~~ comprises one or more pharmaceutically acceptable additives selected from the group consisting of flavouring agents ~~agent~~, colour agents ~~agent~~ and sweetening agents ~~agent~~.

5. (Currently amended) A method for the treatment of gastrointestinal disorders comprising the oral administration of an aqueous suspension via a gastric tube ~~of a~~ or syringe to a patient in need of such treatment, wherein the aqueous suspension comprises (a) a therapeutically effective amount of ~~composition comprising~~ an acid labile proton pump inhibitor compound in the form of a multiple of enteric coating layered pellets and (b) in a medium in the treatment of gastrointestinal disorders, wherein the medium is a pharmaceutically acceptable viscous aqueous medium, and wherein ~~in which~~ the pellets are dispersed in the viscous aqueous medium to form the aqueous ~~an aqueous suspension and the formed suspension is administered through a gastric tube or syringe to a patient in the need of such treatment.~~
6. (Currently amended) The method according to claim 5, wherein the viscous aqueous medium is selected from the group consisting of yoghurt, sour milk, and syrup ~~and aqueous liquids with a similar viscosity.~~
7. (Original) The method according to claim 5, wherein the viscous aqueous medium is a sugar syrup with a sugar content of at least 63% by weight.
8. (Currently amended) The method according to claim 1 or 5 ~~any of claims 1 and 5~~, wherein the viscosity of the aqueous suspension is in the range of from ~~formulation after gelation should be~~ 0.005 to ~~[-]~~ 10 Pa s, as determined at a shear rate of 10 s^{-1} from a flow-curve recorded on a rheometer equipped with a plate-plate geometry.
9. (Currently amended) The method according to claim 1 or 5 ~~any of claims 1 and 5~~, wherein the viscosity of the aqueous suspension is in the range of from ~~formulation after gelation should be~~ 0.05 to ~~[-]~~ 5 Pa s, as determined at a shear rate of 10 s^{-1} from a flow-curve recorded on a rheometer equipped with a plate-plate geometry.
10. (Currently amended) The method according to claim 1 or 5 ~~any of claims 1 and 5~~, wherein the gastric tube has a ~~aqueous suspension is administered through tubes with the size~~ in the range of from CH 5 to CH 10 (CH= Cherrier).

11. (Currently amended) The method according to claim 1 or 5 ~~any of claims 1 and 5~~, wherein the gastric tube has a ~~aqueous suspension is administered through tubes with the size~~ in the range of from CH10 to CH20 (CH= Cherrier).
12. (Currently amended) The method according to claim 1 or 5 ~~any of claims 1 and 5~~, wherein the proton pump inhibitor compound is selected from the group consisting of ~~compounds known under the generic names~~ omeprazole, lansoprazole, pantoprazole, rabeprazole, tenatoprazole, and esomeprazole and ~~or~~ a pharmaceutically acceptable salt thereof.
13. (Currently amended) The method according to claim 1 or 5 ~~any of claims 1 and 5~~, wherein the amount of proton pump inhibitor compound that is ~~administered active substance is~~ in the range from 1 to [-] 100 mg.
14. (Currently amended) The method according to claim 1, wherein the aqueous carrier is selected from the group consisting of water, fruit juice, syrup and dairy products.
15. (Currently amended) The method according to claim 1 ~~any of claims 1-5~~, wherein the amount of aqueous carrier ~~administered viscous medium is~~ in the range from approximately 1 to [-] 35 mL.
16. (Currently amended) A solid ~~Solid~~ composition comprising a proton pump inhibitor compound in the form of a multiple of enteric coating layered pellets, wherein the pellets are in admixture with one or more thickeners capable of forming a viscous suspension ~~medium~~ when dispersed in an aqueous carrier.
17. (Currently amended) The [A] composition according to claim 16, wherein the enteric coated pellets are spherical and have a diameter [size] of less than 1 mm.

18. (Currently amended) **The** [A] composition according to claim 16, wherein the enteric coated pellets are spherical and have a **diameter** [size] of less than 0.5 mm.

Claim 19 (Canceled)

Claim 20 (Canceled)